Andere talen Tonix Pharmaceuticals Holding Corp.

Aandelen

TNXP

US8902608541

Geschatte realtime Cboe BZX Andere beurzen 17:15:53 29-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,171 ^USD	+0,59%		-10,21%	-57,67%

01/04	Tonix Pharmaceuticals Holding Corp. Rapporteert winstresultaten voor het vierde kwartaal eindigend op 31 december 2023	CI
01/04	Tonix Pharmaceuticals Holding Corp. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Tonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 (Fc-modified humanized anti-CD40L mAb) at the American Transplant Congress 2024	14:01
Tonix Pharmaceuticals Announces Presentation at the 2024 BIO International Convention	28/05
Tonix Pharmaceuticals : TNX-102 SL for Fibromyalgia and Long COVID	23/05
Tonix Pharmaceuticals to Deliver an Oral Presentation and Present Two Posters at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting	22/05
Tonix Pharmaceuticals Announces Key Findings from Initial Phase of EVERSANA Market Opportunity Analysis for Tonmya™ for the Management of Fibromyalgia	21/05
Tonix Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase	15/05
Tonix Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Highlights	13/05
Tonix Pharmaceuticals : Factsheet	30/04
Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase	24/04
Tonix Pharmaceuticals : Investor Presentation April 2024	19/04
Tonix Pharmaceuticals : TNX-102 SL for Fibromyalgia and Long COVID	09/04
Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01/04
Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights	01/04
Tonix Pharmaceuticals Prices $4.4 Million Direct Offering; Revises Existing Warrant Terms -- Shares Tumble	28/03
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering	28/03
Tonix Pharmaceuticals Gets Rare Pediatric Disease Label For TNX-2900 to Treat Prader-Willi Syndrome	25/03
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome	25/03
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting	21/03
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues At the American Chemistry Society Spring 2024 Meeting	21/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Tonix Pharmaceuticals Holding Corp.

Aandelen

TNXP

US8902608541

Andere talen

Filters